Ocrelizumab clinical trial results announced

Ocrelizumab was better than beta interferon at reducing the number of relapses, slowing the rate of disability progression and reducing the number of lesions seen on MRI scans according to trial results announced by the pharmaceutical company Roche.
Source: Multiple Sclerosis Trust - Category: Neurology Source Type: news